ghk-cu clinical trials evidence Epigenetic mechanisms activated by increase skin collagen density in trial GHK-Cu Dosing: 1.7mg/Day Injectable (2026)

GHK-Cu addresses structural aging (skin, hair, connective tissue), while NAD+ addresses functional aging (energy metabolism, DNA repair, cognitive sharpness)

By activating transforming growth factor (TGF)-1, the BPC-157 peptide leads to an increased number of capillaries without an increase in their diameter, advanced formation of skin reticulin and collagen fibers, and an increased number of preserved hair follicles

And according to one of the longest (6-8 years) human clinical trials ever done for #TherapeuticPeptides, combining Epitalon with #Thymalin may result in a much lower mortality rate compared to using either peptide in isolation

However, once the neuropathic pain was established, NS-398 showed no effect on pain behavior

Vitamin B12 has the potential to negatively interact with certain prescription medications

But does B12 help sciatica